Who is sponsoring NCT06236555?

NCT06236555 is sponsored by Eda Cetin Ozdemir.

What drugs are being tested in NCT06236555?

Interventions in NCT06236555: 8-iso Prostaglandin F2α and Adenosine Deaminase.

What condition does NCT06236555 study?

NCT06236555 studies Periodontal Diseases.

Is NCT06236555 still recruiting?

NCT06236555 is currently completed. Last updated 1 February 2024.

Last reviewed 2024-02-01 · How we verify

NCT06236555

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Exploring 8-iso Prostaglandin F2α and Adenosine Deaminase Levels in Periodontal Health and Disease

Completed NA Last updated 1 February 2024

What this trial tests

NA trial testing 8-iso Prostaglandin F2α and Adenosine Deaminase in Periodontal Diseases in 80 participants. Completed in 15 January 2024.

Timeline

1 October 2023

Primary endpoint
31 December 2023

15 January 2024

Quick facts

Lead sponsor	Eda Cetin Ozdemir
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	80
Start date	1 October 2023
Primary completion	31 December 2023
Estimated completion	15 January 2024
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

8-iso Prostaglandin F2α and Adenosine Deaminase

Conditions studied

Periodontal Diseases — all drugs for Periodontal Diseases →

Sponsor

Eda Cetin Ozdemir

Who can join

Adults 18 to 65, any sex, with Periodontal Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to assess the diagnostic potential of gingival crevicular fluid (GCF) biomarkers, specifically 8-iso Prostaglandin F2α (8-iso-PGF2α) and adenosine deaminase (ADA), in evaluating periodontal health and disease conditions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Periodontal Diseases

Currently open trials in the same condition.

NCT07358104 — Efficacy of Camel Whey Protein and Camel Whey Protein Nanoparticles for Treating Intra-bony Periodontal Defects · NA · active not recruiting
NCT07312045 — HALP Score, Blood-Based Inflammatory Indices, and Salivary MMP-8 in Periodontal Disease and Healing After Non-Surgical T · recruiting
NCT07384221 — Periodontal Status and Disease Severity in Pemphigus Vulgaris Patients · recruiting
NCT07530978 — ORAL HYGIENE, PERIODONTAL STATUS AND QUALITY OF LIFE · recruiting
NCT06848790 — Interdental Hygiene Methods in Young Adults · NA · recruiting

Other Eda Cetin Ozdemir trials

Trials by the same sponsor.

NCT06993818 — Asprosın And Tumor Necrosıs Factor-α Levels In Type 2 Dıabetıc Chronıc Periodontitis · completed
NCT06700161 — Investigation of Lipoxin A4, Annexin A1 and Interleukin-1 Beta Levels in Individuals With Periodontitis. · completed
NCT06101524 — Volumetric Changes in Free Gingival Graft Procedures Taken With Different Techniques · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06236555 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eda Cetin Ozdemir
Last refreshed: 1 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06236555.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing